Contrasting Metabolic Effects of Antihypertensive Agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 3, 2003, Pages 1104-1111

  Velliquette, Rodney A ^a   Ernsberger, Paul ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; C PEPTIDE; CHOLESTEROL; FATTY ACID; GLUCAGON; HYDRALAZINE; INSULIN; METHYLDOPA; MOXONIDINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HYPERLIPIDEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; C-PEPTIDE; CHOLESTEROL; EATING; FATTY ACIDS, NONESTERIFIED; GLUCAGON; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN; LIPID METABOLISM; MALE; METABOLISM; RATS; RATS, INBRED SHR; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; SYMPATHETIC NERVOUS SYSTEM; TRIGLYCERIDES; VASCULAR RESISTANCE;

EID: 0344304778     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.054221     Document Type: Article

References (37)

1. Bauduceau B, Mayaudon H, and Dupuy O (2000) Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 7:57-61.
2. Benfield GF and Hunter KR (1982) Oxprenolol, methyldopa and lipids in diabetes mellitus. Br J Clin Pharmacol 13:219-222.
3. 2-adrenoceptor antagonist efaroxan in relation to plasma glucose and insulin levels in the rat. Eur J Pharmacol 213:205-212.
4. Chan CKS and Head GA (1996) Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J Hypertens 14:855-864.
5. De Luca N, Izzo R, Fontana D, Iovino G, Argenziano L, Vecchione C, and Trimarco B (2000) Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. J Hypertens 18:1515-1522.
6. 1-imidazoline receptor agonist. J Cardiovasc Pharmacol 35:S27-S41.
7. 1-imidazoline sites. J Pharmacol Exp Ther 264:172-182.
8. 1-Imidazoline receptors: definition, characterization, distribution and transmembrane signalling. Ann NY Acad Sci 763:22-42.
9. Ernsberger P, Ishizuka T, Liu S, Farrell CJ, Bedol D, Koletsky RJ, and Friedman JE (1999) Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 288:139-147.
10. Ernsberger P, Koletsky RJ, Collins LA, and Bedol DL (1996) Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central symaptholytic agent. Cardiovasc Drugs Ther 10:275-282.
11. Ernsberger P, Koletsky RJ, and Friedman JE (1998) Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease. Rev Contemp Pharmacother 9:411-428.
12. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, and Lambert G (2001) Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 14:304S-309S.
13. Fernandez-Real JM and Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278-301.
14. Friedman JE, Ishizuka T, Liu S, Farrell CJ, Bedol DL, Koletsky RJ, Kaung HL, and Ernsberger P (1997) Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273:1014-1023.
15. Haenni A and Lithell H (1999) Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 17 (Suppl 3):S29-S35.
16. Henriksen EJ, Jacob S, Fogt DL, Youngblood EB, and Gödicke J (1997) Antihypertensive agent moxonidine enhances muscle glucose transport in insulin-resistant rats. Hypertension 30:1560-1565.
17. Hirose H, Maruyama H, Itoh K, Koyama K, Kido K, and Saruta T (1992) alpha-2 Adrenergic agonism stimulates islet glucagon release from perfused rat pancreas: possible involvement of alpha-2A adrenergic receptor subtype. Acta Endocrinol 127:279-283.
18. Imazu M (2002) Hypertension and insulin disorders. Curr Hypertens Rep 4:477-482.
19. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, and Brant DO (1993) Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21:618-623.
20. Julius S, Gudbrandsson T, Jamerson K, and Andersson O (1992) The interconnection between sympathetics, microcirculation and insulin resistance in hypertension. Blood Press 1:9-19.
21. Koletsky RJ, Friedman JE, and Ernsberger P (2001) The obese spontaneously hypertensive rat (SHROB, Koletsky rat): a model of metabolic syndrome X, in Animal Models of Diabetes: A Primer (Sima AAF and Shafrir E eds) pp 143-158, Harwood, Singapore.
22. Piletz JE, Ivanov TR, Sharp JD, Ernsberger P, Chang CH, Pickard RT, Gold G, Roth B, Zhu H, Jones JC, et al. (2000) Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization. DNA Cell Biol 19:319-329.
23. Piletz JE, Jones JC, Zhu H, Bishara O, and Ernsberger P (1999) Imidazoline receptor antisera-selected cDNA clone and mRNA distribution. Ann NY Acad Sci 881:1-7.
24. Pitre M, Gaudreault N, Santure M, Nadeau A, and Bachelard H (1999) Isradipine and insulin sensitivity in hypertensive rats. Am J Physiol 276:E1038-E1048.
25. Rabbia F, Martini G, Cat GG, Milan A, Chiandussi L, and Veglio F (2001) Antihypertensive drugs and sympathetic nervous system. Clin Exp Hypertens 23:101-111.
26. Rosen P, Ohly P, and Gleichmann H (1997) Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 15 (Suppl 1):S31-S38.
27. Sabbatini M, Bellagamba G, Vega JA, and Amenta F (2001) Effect of antihypertensive treatment on peripheral nerve vasculature in spontaneously hypertensive rats. Clin Exp Hypertens 23:157-166.
28. Sanbar SS and de Romero SA (1969) Action of hydralazine on glucose turnover and plasma lipids in dogs. Metabolism 18:292-299.
29. Szabo B (2002) Imidazoline antihypertensive drugs: a critical review on their mechanisms of action. Pharmacol Ther 93:1-35.
30. Tabei R, Spector S, Louis WJ, and Sjoerdsma A (1970) Effects of antihypertensive drugs in the spontaneously hypertensive rat. Clin Pharmacol Ther 11:269-274.
31. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K, and Koletsky RJ (1996) Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 14:130-131.
32. Toborek M, Lee YW, Garrido R, Kaiser S, and Hennig B (2002) Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 75:119-125.
33. Tolentino-Silva FP, Haxhiu MA, Ernsberger P, Waldbaum S, and Dreshaj IA (2000) Differential cardiorespiratory control elicited by activation of ventral medullary sites in mice. J Appl Physiol 89:437-444.
34. 2-adrenergic receptors. FASEB J 17:A234.
35. Velliquette RA, Koletsky RJ, and Ernsberger P (2002) Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Exp Biol Med 227:164-170.
36. Yakubu-Madus FE, Johnson WT, Zimmerman KM, Dananberg J, and Steinberg MI (1999) Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic fatty rat model of type 2 diabetes. Diabetes 48:1093-1100.
37. 2A-adrenoceptor transgenic mice. Br J Pharmacol 126:1522-1530.